text.skipToContent text.skipToNavigation

Maximum quantity allowed is 999

Please select the quantity

CAS RN: 25316-40-9 | Product Number: D4193

Doxorubicin Hydrochloride

Purity: >95.0%(HPLC)
  • Hydroxydaunorubicin Hydrochloride
15   ≥20 
9   ≥20 

*Stock available in Belgium will be delivered in 1 to 3 days
*Stock available in Japan will be delivered in 1 to 2 weeks (excludes regulated items and dry ice shipments).

Product Number D4193
Purity / Analysis Method >95.0%(HPLC)
Molecular Formula / Molecular Weight C__2__7H__2__9NO__1__1·HCl = 579.98  
Physical State (20 deg.C) Solid
Storage Temperature 0-10°C
Condition to Avoid Light Sensitive,Heat Sensitive
CAS RN 25316-40-9
Related CAS RN 23214-92-8
Reaxys Registry Number 4229251
PubChem Substance ID 253660149
Merck Index (14) 3439
MDL Number


Appearance Light yellow to Yellow to Orange powder to crystal
Purity(HPLC) min. 95.0 area%
Specific rotation [a]20/D +240 to +270 deg(C=0.1,MeOH)
Properties (reference)
Specific Rotation 248° (C=0.1,MeOH)
Maximum Absorption Wavelength 497(H2O) nm
Solubility in water Soluble
Solubility (soluble in) Tetrahydrofuran,Methanol
Solubility (insoluble in) Ether,Benzene,Chloroform,Acetone
Pictogram Pictogram Pictogram
Signal Word Warning
Hazard Statements H302 : Harmful if swallowed.
H361 : Suspected of damaging fertility or the unborn child.
H373 : May cause damage to organs through prolonged or repeated exposure.
H351 : Suspected of causing cancer.
Precautionary Statements P501 : Dispose of contents/ container to an approved waste disposal plant.
P260 : Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.
P201 : Obtain special instructions before use.
P264 : Wash skin thoroughly after handling.
P280 : Wear protective gloves/ protective clothing/ eye protection/ face protection.
P308 + P313 : IF exposed or concerned: Get medical advice/ attention.
Related Laws: / Compliance with laws, Regulations
Enzyme Commission 246-818-3
RTECS# QI9295900
Transport Information:
HS Number 2941900000
Reagent for nephritis (glomerulonephritis) model

Adriamycin-induced nephrotic syndrome in rats: sequence of pathologic events

T. Bertani, A. Poggi, R. Pozzoni, F. Delaini, G. Sacchi, Y. Thoua, G. Mecca, G. Remuzzi, M. B. Donati, Lab. Invest. 1982, 46, 16.

Adriamycin-induced chronic proteinuria: a structural and functional study

M. P. O'Donnell, L. Michels, B. Kasiske, L. Raij, W. F. Keane, J. Lab. Clin. Med. 1985 106, 62.

Effect of dietary protein restriction on renal purines and purine-metabolizing enzymes in adriamycin nephrosis in rats: a mechanism for protection against acute proteinuria involving xanthine oxidase inhibition

G. M. Ghiggeri, F. Ginevri, G. Cercignani, R. Oleggini, A. Garberi, G. Candiano, P. Altieri, R. Gusmano, Clin. Sci. (Lond). 1990, 79, 647.

Effect of enalapril on adriamycin-induced nephrosis

K. C. Irwin, B. H. Brouhard, S. Satoh, N. T. Stowe, Pediatr. Nephrol. 1992, 6, 448.

Erlotinib preserves renal function and prevents salt retention in doxorubicin treated nephrotic rats

R. N. Bou Mata, J. D. Klein, J. M. Sands, PLOS ONE. 2013, 8, 54738.

Protective effects of sinomenine against doxorubicin-induced nephrosis in rats

J. Zhang, R. Hu, Z. K. Xia, X. G. Ren, L. W. Zhang, Y. H. Liang, G. L. Liu, J. Asian Nat. Prod. Res. 2012, 14, 678.

Reagent for cardiomyopathy model

Adriamycin-induced cardiac damage in the mouse: a small-animal model of cardiotoxicity

S. H. Rosenoff, H. M. Olson, D. M. Young, F. Bostick, R. C. Young, J. Natl. Cancer Inst. 1975, 55, 191.

Experimental animal models of adriamycin cardiotoxicity

J. H. Doroshow, G. Y. Locker, C. E. Myers, Cancer Treat. Rep. 1979, 63, 855.

Adriamycin-induced cardiomyopathy. A rat model

A. Czarnecki, A. Hinek, D. Sołtysiak-Pawluczuk, Pol. J. Pharmacol. Pharm. 1986, 38, 171.

Chronic doxorubicin induced cardiomyopathy in rabbits: mechanical, intracellular action potential, and beta adrenergic characteristics of the failing myocardium

H. Shenasa, A. Calderone, M. Vermeulen, P. Paradis, H. Stephens, R. Cardinal, J. de Champlain, J. L. Rouleau, Cardiovasc. Res. 1990, 24, 591.

Serial assessment of myocardial properties using cyclic variation of integrated backscatter in an adriamycin-induced cardiomyopathy rat model

J. W. Ha, S. M. Kang, W. B. Pyun, J. Y. Lee, M. Y. Ahn, W. C. Kang, T. J. Jeon, N. Chung, J. D. Lee, S. H. Cho, Yonsei Med. J. 2005, 46, 73.

Improvement of doxorubicin induced cardiomyopathy in rats treated with insulin-like growth factor I

G. R. Ambler, B. M. Johnston, L. Maxwell, J. B. Gavin, P. D. Gluckman, Cardiovasc. Res. 1993, 27, 1368.

Intracoronary infusion of skeletal myoblasts improves cardiac function in doxorubicin-induced heart failure

K. Suzuki, B. Murtuza, N. Suzuki, R. T. Smolenski, M. H. Yacoub, Circulation 2001, 104, I213.

Doxorubicin dose for congestive heart failure modeling and the use of general ultrasound equipment for evaluation in rats Longitudinal in vivo study.

M. Spivak, R. Bubnov, I. Yemets, L. Lazarenko, N. Timoshok, A. Vorobieva, S. Mohnatyy, Z. Ulberg, L. Reznichenko , T. Grusina, V. Zhovnir, N. Zholobak, Med. Ultrason. 2013, 15, 23.

Reagent for nausea or vomiting model

The antiemetic effect of a novel tropisetron patch in anticancer agents-induced kaolin pica model using rats

S. W. Jeong, J. W. Cho, J. S. Hwang, J. D. Song, S. Shin, J. Y. Jang, S. Y. Hwang, O. Kim, J. C. Kim, Y. B. Kim, J. K. Kang, Environ. Toxicol. Pharmacol. 2005, 20, 167.

Reviews on an Anti-tumor Anthracycline Antibiotic, Doxorubicin

Doxorubicin is a widely used anti-tumor anthracycline antibiotic which exhibits good activity against a wide range of tumors. Doxorubicin interacts with DNA by intercalation and inhibition of DNA replication.


PubMed Literature

Safety Data Sheet (SDS) Search
Please select Language.

The requested SDS is not available.

• Please check that the Product Number you have entered is correct.

• If your information is correct and you are still not able to view the requested SDS,  please Contact Us for more information.

C of A & Other Certificates
Please enter Lot Number Incorrect Lot Number is entered
Other Documents

Life Science